Market Cap 5.08B
Revenue (ttm) 329.00M
Net Income (ttm) 23.38M
EPS (ttm) N/A
PE Ratio 11.01
Forward PE 10.60
Profit Margin 7.11%
Debt to Equity Ratio 0.40
Volume 1,164,800
Avg Vol 1,797,982
Day's Range N/A - N/A
Shares Out 158.76M
Stochastic %K 66%
Beta 2.01
Analysts Strong Sell
Price Target $44.28

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's de...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 554 4484
Fax: 212 554 4531
Address:
3020 Carrington Mill Blvd., Suite 475, Morrisville, United States
RapidFury
RapidFury Dec. 13 at 6:37 PM
ARBB broke out on Friday, Setting itself up for a parabolic move up. Keep it on that watchlist. They are sending all these micro float cap tickers on insane rallies recently. Would not even be shocked if they send ARBB for 500% next. Only 640k shares outstanding to buy 💎 Adders on $ABCL $FBIO $SNDX $TGTX next
0 · Reply
BioHedge
BioHedge Dec. 13 at 5:09 PM
$TGTX What are they waiting for?
0 · Reply
calbucs
calbucs Dec. 13 at 4:55 PM
$TGTX Paid per post hoes like this Bot are more and more frequent here , they will do 1Bill in revs next year , are cash flow positive and have now done 2 -100 mill buybacks in just over 1year ! Stop your DA comments and postings , selling your soul for peanuts is desperate .
0 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Dec. 13 at 4:35 PM
1 · Reply
Diefreeandsell
Diefreeandsell Dec. 13 at 3:40 PM
$CAPR lets discuss bo potential. when do you think it will happen and who will be the buyer? Keep in mind that In essence, the sweet spot for a biotech company is when its lead asset has demonstrated strong human efficacy data, maximizing its value to potential acquirers. By the way I was spot on when Aveo $CCXI $RXDX $CDTX where bought out. I was wrong w $TGTX but that worked out pretty good too! Most bo targets have compelling late stage trial results followed by offering after huge gap up that never closes the gap, continues to hold above the offering price and may even continue to trend up as tutes accumulate shares. Sound familiar?
4 · Reply
Sciguy67
Sciguy67 Dec. 13 at 2:19 AM
$TGTX 40’s by mid 2026. Sub Q filed in Nov 50-60 BO mid 2027 share price?
2 · Reply
ians
ians Dec. 12 at 8:09 PM
$TGTX As MW quipped, "why a BTKi?!"🤦‍♂️ Would like to hear Roche's rationale. Cuz Briumvi's ARR is superior to Fenebrutinib 🥇☘️💎 https://grok.com/share/bGVnYWN5_a4e0b3a5-9cfe-43b1-b215-1872ecd94f7a
0 · Reply
SteveTexans
SteveTexans Dec. 12 at 8:01 PM
$TGTX https://www.facebook.com/share/p/1FXpf99x97/?mibextid=wwXIfr Never see any patients mention BRIUMVI. Most post are about Ocervus. I have respectfully posted there look at BRIUMVI with webpage links. 👎👎😡
0 · Reply
StockDreamin
StockDreamin Dec. 12 at 3:56 PM
$TGTX cmon cmon
0 · Reply
Diefreeandsell
Diefreeandsell Dec. 12 at 3:52 PM
$IBRX For those that believe Volume precedes price and want an opp to buy while mm's change their hedges and subdue SP: VOLUME 10.03mil shares, +262% compared to typical volume of 2.77mil by 10:45 am ET. High Volume alert! Typical daily volume is 9.24mil shares over the past 6 months. As stated in the EMA announcement, the benefit of a medicine’s immediate availability to patients outweighs the inherent risks.” “ANKTIVA offers a new treatment option for patients and addresses an important unmet need,” the EMA noted in an announcement on the recommendation. “There are currently no authorized treatments for NMIBC that does [sic] not respond to BCG.” The European Association of Urology and World Bladder Cancer Patient Coalition estimate that more than 200,000 patients will be diagnosed with bladder cancer in 2025. Approximately 75% of these patients (150,000) will have NMIBC, and is the most common form of bladder cancer. $ALT $TGTX ☝️ $CAPR $XBI
0 · Reply
Latest News on TGTX
TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 11:56 AM EST - 5 weeks ago

TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript


TG Therapeutics Q2 Revenue Up 91%

Aug 4, 2025, 12:23 PM EDT - 4 months ago

TG Therapeutics Q2 Revenue Up 91%


TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 10:19 AM EDT - 4 months ago

TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript


TG Therapeutics: Estimates Could Soon Be Raised Again

May 28, 2025, 6:00 AM EDT - 7 months ago

TG Therapeutics: Estimates Could Soon Be Raised Again


Why TG Therapeutics Stock Was Tumbling Today

May 5, 2025, 3:37 PM EDT - 7 months ago

Why TG Therapeutics Stock Was Tumbling Today


TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:55 AM EDT - 7 months ago

TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript


Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher

Mar 21, 2025, 11:50 AM EDT - 9 months ago

Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher


Why TG Therapeutics Stock Was Soaring This Week

Mar 7, 2025, 5:23 PM EST - 10 months ago

Why TG Therapeutics Stock Was Soaring This Week


TG Therapeutics: A Wonderful Hold

Mar 3, 2025, 3:59 PM EST - 10 months ago

TG Therapeutics: A Wonderful Hold


TG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 11:55 AM EST - 10 months ago

TG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript


TG Therapeutics: 2025 Revenues Will Smash Expectations

Jan 21, 2025, 2:17 AM EST - 11 months ago

TG Therapeutics: 2025 Revenues Will Smash Expectations


TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst

Jan 13, 2025, 11:38 PM EST - 11 months ago

TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst


RapidFury
RapidFury Dec. 13 at 6:37 PM
ARBB broke out on Friday, Setting itself up for a parabolic move up. Keep it on that watchlist. They are sending all these micro float cap tickers on insane rallies recently. Would not even be shocked if they send ARBB for 500% next. Only 640k shares outstanding to buy 💎 Adders on $ABCL $FBIO $SNDX $TGTX next
0 · Reply
BioHedge
BioHedge Dec. 13 at 5:09 PM
$TGTX What are they waiting for?
0 · Reply
calbucs
calbucs Dec. 13 at 4:55 PM
$TGTX Paid per post hoes like this Bot are more and more frequent here , they will do 1Bill in revs next year , are cash flow positive and have now done 2 -100 mill buybacks in just over 1year ! Stop your DA comments and postings , selling your soul for peanuts is desperate .
0 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Dec. 13 at 4:35 PM
1 · Reply
Diefreeandsell
Diefreeandsell Dec. 13 at 3:40 PM
$CAPR lets discuss bo potential. when do you think it will happen and who will be the buyer? Keep in mind that In essence, the sweet spot for a biotech company is when its lead asset has demonstrated strong human efficacy data, maximizing its value to potential acquirers. By the way I was spot on when Aveo $CCXI $RXDX $CDTX where bought out. I was wrong w $TGTX but that worked out pretty good too! Most bo targets have compelling late stage trial results followed by offering after huge gap up that never closes the gap, continues to hold above the offering price and may even continue to trend up as tutes accumulate shares. Sound familiar?
4 · Reply
Sciguy67
Sciguy67 Dec. 13 at 2:19 AM
$TGTX 40’s by mid 2026. Sub Q filed in Nov 50-60 BO mid 2027 share price?
2 · Reply
ians
ians Dec. 12 at 8:09 PM
$TGTX As MW quipped, "why a BTKi?!"🤦‍♂️ Would like to hear Roche's rationale. Cuz Briumvi's ARR is superior to Fenebrutinib 🥇☘️💎 https://grok.com/share/bGVnYWN5_a4e0b3a5-9cfe-43b1-b215-1872ecd94f7a
0 · Reply
SteveTexans
SteveTexans Dec. 12 at 8:01 PM
$TGTX https://www.facebook.com/share/p/1FXpf99x97/?mibextid=wwXIfr Never see any patients mention BRIUMVI. Most post are about Ocervus. I have respectfully posted there look at BRIUMVI with webpage links. 👎👎😡
0 · Reply
StockDreamin
StockDreamin Dec. 12 at 3:56 PM
$TGTX cmon cmon
0 · Reply
Diefreeandsell
Diefreeandsell Dec. 12 at 3:52 PM
$IBRX For those that believe Volume precedes price and want an opp to buy while mm's change their hedges and subdue SP: VOLUME 10.03mil shares, +262% compared to typical volume of 2.77mil by 10:45 am ET. High Volume alert! Typical daily volume is 9.24mil shares over the past 6 months. As stated in the EMA announcement, the benefit of a medicine’s immediate availability to patients outweighs the inherent risks.” “ANKTIVA offers a new treatment option for patients and addresses an important unmet need,” the EMA noted in an announcement on the recommendation. “There are currently no authorized treatments for NMIBC that does [sic] not respond to BCG.” The European Association of Urology and World Bladder Cancer Patient Coalition estimate that more than 200,000 patients will be diagnosed with bladder cancer in 2025. Approximately 75% of these patients (150,000) will have NMIBC, and is the most common form of bladder cancer. $ALT $TGTX ☝️ $CAPR $XBI
0 · Reply
twakey
twakey Dec. 12 at 3:08 PM
$TGTX GIA will sink it down to $20S, buy out could pull it up to $68.
1 · Reply
fodness
fodness Dec. 12 at 2:43 PM
$TGTX really wanted to touch 100 day, let’s try again
1 · Reply
SGL_FGHI
SGL_FGHI Dec. 12 at 2:41 PM
$TGTX Stop loss shoppers doing their thing, can't blame them.
0 · Reply
no1chode
no1chode Dec. 12 at 1:55 PM
$TGTX let’s get some more love today 🍀
0 · Reply
InvestingIsFun45
InvestingIsFun45 Dec. 12 at 1:37 PM
0 · Reply
Rickerthestockpicker
Rickerthestockpicker Dec. 12 at 11:06 AM
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 6:34 AM
Enter: $TGTX Calls Strike Price: $31 Expiry Date: JAN 16 2026 Buy in Price: $2.10 - $3.00 Sell Price: $3.46 Profit : +65% (Turn every $1 into $1.65) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
TroyTiger
TroyTiger Dec. 12 at 3:40 AM
$TGTX 484 $35 Jan Calls bought Thursday. Stock up 4%+ on the day with decent buying volume.... I like it :)
0 · Reply
ern1in
ern1in Dec. 12 at 2:52 AM
$TGTX Just saw a k commercial ..... 🤢🤢🤢🤢🤢🤮🤮🤮🤮🤮🤮🤮🤮
0 · Reply
financiern
financiern Dec. 12 at 2:18 AM
$TGTX if revenue keeps growing the way we expect, and we’re talking mid 200 mil a quarter next year, an ongoing quarterly 100 mil buyback should be easily attainable. Price will move once the float gets eaten up. Can’t wait.
1 · Reply
ians
ians Dec. 12 at 2:03 AM
$TGTX Remember ITCI BO by JNJ for $14.6B🤔 That's MW BO comparable.👍 $14.6B/ $4.9B * $32/sh = ~$95/sh BO price tag 🤑☘️💎 https://stocktwits.com/ians/message/638953397
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:17 AM
Actionable Trade Alert for $TGTX: Market Context: $TGTX is currently trading at $31.41, showing a moderate RSI of 55.32, indicating a neutral to slightly bullish momentum. The stock is positioned between its 60D high of $37.55 and low of $29.50, suggesting potential for upward movement. Directional Bias: The stock's price is below both the 30-day moving average (MA30) of $31.86 and the 50-day moving average (MA50) of $33.07, indicating a potential reversal opportunity. The RSI is not overbought, allowing for further upside potential. Trade Plan: - Suggested Entry: $31.50 - Stop Loss: $29.50 (below the 60D low) - Take Profit Targets: 1. $33.00 (6% gain) 2. $35.00 (11.5% gain) 3. $36.75 (17% gain) This trade plan offers a clear path to capitalize on potential upward movement while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply